1. Medtech Insight
  2. >>Archive

St. Jude Halts Portico TAVR Implants Based On IDE Study Imaging Data

The firm says it is temporarily halting implants of its transcatheter aortic health valve replacement worldwide while it reviews CT data showing reduced valve leaflet mobility in some patients treated as part of St. Jude’s U.S. pivotal trial.

St. Jude Medical Inc. confirms that it has temporarily halted all new implants of its Portico transcatheter aortic heart valve replacement based on imaging data showing reduced mobility in the valve leaflets for some patients enrolled in the firm’s U.S. investigational device exemption study.

The worldwide “pause” in implants will give the company “time to evaluate recent cases of reduced valve leaflet mobility that...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

CMS Announces $50B In Grants For Rural Health Transformation

AdvaMed has praised CMS’ Rural Health Transformation Program, which will allocate $50 billion over five years to enhance rural healthcare. States can apply for grants by Nov. 5 to develop sustainable healthcare systems and improve patient outcomes.

Mental Health The Focus Of Upcoming Digital Health Advisory Committee Meeting

 
• By Brian Bossetta

The US FDA will hold a public meeting of its Digital Health Advisory Committee in November to focus on generative AI-enabled medical devices to treat mental health.

Morphic Medical Prepares RESET Rollout In UK And Germany, Eyes Global Expansion In 5 Years

 
• By Shubham Singh

The company is undergoing major leadership changes, having appointed 30-year medtech veteran Jane Wright as chief financial officer on Sept. 12. Wright’s appointment follows Gutteridge’s own transition to CEO earlier this year.